Search

Displaying results 6061 - 6070 of 10000 in total
  1. Drug

    Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16910
    Approved

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  2. Drug

    Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16914
    ApprovedWithdrawn

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  3. Drug

    Influenza A virus A/Delaware/55/2019 CVR-45 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16915
    ApprovedWithdrawn

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  4. Drug

    Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16919
    ApprovedWithdrawn

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen

  5. Drug

    OM85

    go.drugbank.com/drugs/DB16533
    Investigational

    OM-85, a bacterial extract, is an immunomodulator of interferon-β production and inflammasome activity.

  6. Drug

    TAK-751S

    go.drugbank.com/drugs/DB06432
    Investigational

    TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia coli_.[A260296]

  7. Drug

    rPSGL-Ig

    go.drugbank.com/drugs/DB06256
    Investigational

    Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.

    Synonyms: rPSGL-Ig, rPSGL-1-Ig
  8. Drug

    Dibenzepin

    go.drugbank.com/drugs/DB13225
    Approved

    Dibenzepin is approved for use in Europe.

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  10. Drug

    Gemcabene

    go.drugbank.com/drugs/DB05123
    Investigational

    Gemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).